Evidence map›Paper›PMID 21262323›Full record

ArticleNeuroscience2011

Age-related loss of orexin/hypocretin neurons.

B A Kessler, E M Stanley, D Frederick-Duus, J Fadel

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuroscience, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 2 pooled it
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 2 syntheses or guidelines pooled it, 107 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

B A KesslerUniversity of South Carolina School of Medicine, Department of Pharmacology, Physiology and Neuroscience, 6439 Garners Ferry Road Columbia, SC 29208, USA.
E M Stanley
D Frederick-Duus
J Fadel
University of South Carolina · US

Funding

Aging, acetylcholine and the hypothalamusR01AG030646 · NIA · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI FADEL, JIM R · 2008 to 2011
$1.2M
NIA NIH HHS R01 AG030646NIA NIH HHS R01AG030646
6 · The paper itself

Abstract

Aging is associated with many physiological alterations-such as changes in sleep patterns, metabolism and food intake-suggestive of hypothalamic dysfunction, but the effects of senescence on specific hypothalamic nuclei and neuronal groups that mediate these alterations is unclear. The lateral hypothalamus and contiguous perifornical area (LH/PFA) contains several populations of neurons, including those that express the neuropeptides orexin (hypocretin) or melanin-concentrating hormone (MCH). Collectively, orexin and MCH neurons influence many integrative homeostatic processes related to wakefulness and energy balance. Here, we determined the effect of aging on numbers of orexin and MCH neurons in young adult (3-4 months) and old (26-28 months) Fisher 344/Brown Norway F1 hybrid rats. Aged rats exhibited a loss of greater than 40% of orexin-immunoreactive neurons in both the medial and lateral (relative to the fornix) sectors of the LH/PFA. MCH-immunoreactive neurons were also lost in aged rats, primarily in the medial LH/PFA. Neuronal loss in this area was not global as no change in cells immunoreactive for the pan-neuronal marker, NeuN, was observed in aged rats. Combined with other reports of altered receptor expression or behavioral responses to exogenously-administered neuropeptide, these data suggest that compromised orexin (and, perhaps, MCH) function is an important mediator of age-related homeostatic disturbances of hypothalamic origin. The orexin system may represent a crucial substrate linking homeostatic and cognitive dysfunction in aging, as well as a novel therapeutic target for pharmacological or genetic restoration approaches to preventing or ameliorating these disturbances.

Indexed as

AgingAnimalsAntigens, NuclearCell CountHypothalamic Area, LateralHypothalamic HormonesIntracellular Signaling Peptides and ProteinsMaleMelaninsModels, AnimalNerve DegenerationNerve Tissue ProteinsNeuronsNeuropeptidesOrexinsPituitary HormonesAntigens, NuclearHypothalamic HormonesIntracellular Signaling Peptides and Proteinsmelanin-concentrating hormoneMelaninsNerve Tissue ProteinsNeuropeptidesOrexinsPituitary HormonesRbfox3 protein, rat

Identifiers

PMID21262323
PMCPMC3048917
OpenAlexW2036187063

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.